Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in COPD or cystic fibrosis
2024-518337-29-00Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Dec 2024
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levofloxacin and piperacillin + tazobactam in chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Antibiotic concentrations in ELF and tissue biopsy and microdialysis. Planned start Dec 2024; status: authorised.
02
Drugs
levofloxacinpiperacillin + tazobactam
03
Conditions
chronic obstructive pulmonary disease (COPD)cystic fibrosis (CF)
Beyond the preview
Go deeper on 2024-518337-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518337-29-00.